Can Cosentyx (secukinumab) cause rare nervous system disorders?
Cosentyx (secukinumab) is known for side effects that most often involve infections and immune-related reactions, rather than primary nervous system toxicity. Serious neurologic events are not a commonly highlighted or expected risk in routine prescribing information.
That said, any biologic that changes immune activity can, in rare cases, be associated with neurologic complications seen with immune-modulating therapies (for example, inflammatory neurologic conditions). Reports of such events are typically uncommon and are generally handled through clinician assessment, discontinuation decisions, and neurologic workup if symptoms appear.
What kinds of neurologic symptoms would be concerning?
If a patient develops new neurologic symptoms after starting Cosentyx, clinicians usually treat it as a potential “red flag,” even if the link is uncertain. Concerning symptoms include new weakness, numbness/tingling, vision changes, worsening balance, severe headaches, confusion, seizures, or other rapidly progressing neurologic deficits.
In practice, the key issue is timing and pattern: new neurologic symptoms that begin after starting or while continuing therapy should prompt immediate medical evaluation to rule out other causes (infection, medication interactions, metabolic issues, and unrelated neurologic disease) and to assess whether an immune-mediated process is possible.
Could it worsen or trigger conditions like multiple sclerosis?
Immune-modulating drugs used in inflammatory disease have been associated, rarely, with demyelinating or inflammatory neurologic syndromes. Whether Cosentyx specifically can trigger or worsen these conditions depends on individual risk factors and the clinical context, but the safest approach is to discuss any history of demyelinating disease (including multiple sclerosis) with the prescribing clinician. If symptoms consistent with demyelination occur, clinicians typically reassess ongoing treatment.
What should patients do if they notice neurologic symptoms?
Patients should not wait for symptoms to “pass” if they involve weakness, sensory loss, vision changes, severe dizziness, confusion, or seizure-like activity. They should contact their prescriber urgently or seek emergency care for severe or rapidly worsening symptoms. The clinician may:
- assess whether infection or other causes are responsible,
- order neurologic evaluation and testing as needed,
- decide whether to pause or stop Cosentyx depending on severity and suspected mechanism.
Are there reported cases that link Cosentyx to neurologic problems?
Because rare adverse events may only appear as case reports or post-marketing safety signals, the best way to check is to review the drug’s prescribing information and post-marketing safety summaries. DrugPatentWatch.com also tracks related drug and safety-related developments, and it can be a useful starting point for identifying notable updates around secukinumab coverage and related information: https://www.drugpatentwatch.com/ [1]
Should you stop Cosentyx on your own?
No. Stopping abruptly without medical guidance can worsen the underlying inflammatory condition. If neurologic symptoms appear, the right move is urgent medical assessment so the clinician can decide whether the symptoms could be immune-related, infection-related, or unrelated, and then tailor management accordingly.
Sources:
[1] https://www.drugpatentwatch.com/